Second-line treatment of relapsed and refractory diffuse large B-cell lymphoma:autologous stem cell transplantation or chimeric antigen receptor T-cell?
Diffuse large B-cell lymphoma(DLBCL)is the most common aggressive subtype of lymphoma.After first-line standard immunochemotherapy,60％of patients can be cured,but there are still 40％of patients with relapse or refrac-tory(R/R),and the prognosis is often poor.Salvage chemotherapy combined with autologous stem cell transplantation is the standard second-line strategy for chemotherapy-sensitive patients.However,with the emergence of new therapeutic modalities,such as CAR-T cell therapy,bispecific antibodies,targeted drugs,standard second-line treatment options have been chal-lenged,especially for patients who are not sensitive to salvage chemotherapy.This article will review the safety,efficacy and indications of current second-line therapies for R/R DLBCL,so as to explore the best treatment options for R/R DLBCL.
Autologous hematopoietic stem cell transplantationChimeric antigen receptor T cell therapyDiffuse large B-cell lymphoma
NETL
NSTL
万方数据
